Pancreatic Cancer Vaccine Shows Remarkable Immune Activation in New Clinical Trial

2026-10-24 companies

Rochester, Saturday, 24 October 2026.
Mayo Clinic trial results show an experimental vaccine triggered a targeted immune response in 98.9% of evaluated pancreatic cancer patients, paving the way for larger late-stage clinical studies.

Breakthrough Trial Results from Mayo Clinic

On Friday, 23 October 2026, Mayo Clinic researchers announced groundbreaking results from a randomized Phase 2 clinical trial evaluating an investigational vaccine targeting KRAS mutations in pancreatic cancer patients [1][5]. The study, published in Nature Medicine, demonstrated that the therapeutic vaccine generated a robust immune response in 98.889% (98.9%) of evaluable patients, representing a significant advancement in oncology therapeutics [1][5]. The trial involved 144 patients with stage I–III KRAS-mutated pancreatic cancer who had previously undergone surgery and chemotherapy, with 96 receiving the vaccine and 48 serving as the observation control group [1][5].

Clinical Outcomes and Immune Response Metrics

While the trial did not meet its primary endpoint of statistically significant improvement in disease-free survival for the entire cohort—recording median recurrence-free survival of 23.8 months for vaccinated patients versus 21.2 months for the control group—the immune response data were compelling [1][5]. Among the 90 patients evaluable for immune response, 89 demonstrated an enhanced T-cell response to mutated KRAS, with 90% (90%) showing a KRAS-specific response more than nine times higher than baseline [1][5]. Additionally, 95.556% (95.5%) maintained a detectable KRAS-specific T-cell response at least 46 weeks post-vaccination, indicating sustained immunological activity [1][5]. Dr. Ben George, M.B.B.S., M.D., lead author and Mayo Clinic medical oncologist, noted, ‘Historically, pancreatic cancer has been very difficult to treat with immunotherapy. What is encouraging is that we were able to generate a strong immune response against KRAS mutations in nearly every patient we evaluated’ [1].

Path Forward: Phase 3 Trial on the Horizon

The Phase 2 trial results provide a strong foundation for advancing to a Phase 3 clinical trial, which researchers plan to design based on the immune response data and exploratory subgroup analyses [1][5]. Dr. George highlighted that patients with greater immune responses to the vaccine appeared to have longer disease-free survival times, though these findings are preliminary and require validation in larger studies [1]. The vaccine targets seven common KRAS mutations by activating CD4 and CD8 T cells in the lymph nodes, addressing a critical driver of pancreatic ductal adenocarcinoma, which accounts for 90% of pancreatic cancer cases [1][5][GPT]. Mayo Clinic spokesperson stated, ‘The immune response is an important signal that helps us understand what is happening biologically and gives us important information for the next trial’ [1].

Broader Implications for Cancer Immunotherapy

The trial’s success underscores the potential of targeted mRNA and peptide vaccine platforms in oncology, particularly for cancers historically resistant to immunotherapy [1][5]. While KRAS mutations are present in nearly all pancreatic cancers, their role in other malignancies, such as colorectal and lung cancers, suggests broader applications for this vaccine technology [GPT]. Mayo Clinic’s announcement follows closely on the heels of related research, including a study from the Karlsruhe Institute of Technology (KIT) published in Cell Death & Disease, which identified molecular mechanisms regulating the tumor microenvironment in pancreatic cancer [7]. KIT researchers focused on CD44, a molecule that controls cancer-associated fibroblasts, offering complementary insights into overcoming therapeutic resistance [7]. These developments collectively highlight a growing momentum in pancreatic cancer research, with immunotherapy and tumor microenvironment modulation emerging as dual pillars of innovation [7][GPT].

Sources

Biotechnology Oncology